News | May 17, 2010

Organization Promotes Quality Care in Cath Labs

May 17, 2010 – The Society for Cardiovascular Angiography and Interventions (SCAI) recently announced the creation of the Accreditation for Cardiovascular Excellence (ACE) organization. The new accrediting body, announced at SCAI’s 33rd Annual Scientific Sessions in early May, is designed to promote and uphold high-quality patient care and improve patient safety in facilities where invasive cardiac and endovascular procedures are performed.

ACE will advance excellence by providing an accrediting mechanism, based on scientific evidence in peer-reviewed medical literature and professionally determined quality metrics, to ensure processes and outcomes of cardiovascular procedures are consistent with predetermined benchmarks. ACE also makes available tools and quality improvement guidance to organizations seeking, or having achieved provisional accreditation, in order to support ongoing quality improvement and optimal patient care.

“Our primary goal for ACE is to increase the consistency of superior patient care in cardiovascular procedures throughout the U.S.,” said Bonnie Weiner, M.D., MSEC, MBA, FSCAI, president of ACE and director of interventional cardiology research at Saint Vincent Hospital at Worcester Medical Center, Worcester, Mass. “When they are treated at a cardiovascular center that is ACE-accredited, patients should feel confident the facility has taken the appropriate, evidence-based steps to help ensure the best care for each individual patient.”

Carotid Stenting
ACE will first focus on providing accreditation to hospitals that perform carotid artery stenting procedures, with subsequent expansion to other cardiovascular procedures, including percutaneous coronary interventions, other endovascular procedures and structural heart disease interventions. Currently, carotid artery stenting is reserved primarily for patients who are at high-risk for carotid endarderectomy.

“Advancing quality standards is of utmost importance in our field and in all of medicine,” said Steven R. Bailey, M.D., FSCAI, chief, division of cardiology, Janey Briscoe distinguished chair of cardiovascular research and professor of medicine and radiology at the University of Texas Health Sciences Center at San Antonio and SCAI president. “ACE will help us to work proactively to promote and maintain excellence for the patients we serve.”

ACE will begin accrediting carotid artery stenting facilities this summer. Facilities must apply for accreditation, submit data and be visited by review teams to complete the process. Part of the accreditation process will include validation of self-reported data and appropriate use of existing guidelines and knowledge of changing best practices. Accreditation will last for a two-year period, after which a review of the facility will be required for continued ACE recognition.

For more information:

Related Content

Videos | Cath Lab| January 04, 2018
Bernadette Speiser, BSN, MSN, CCRN, RCIS, a cardiac cath/EP nurse at Palo Alto Veterans Hospital, Palo Alto, Calif.,
FDA Initiates Class I Recall of Sterilmed Reprocessed Agilis Steerable Introducer Sheath
News | Cath Lab| January 04, 2018
The U.S. Food and Drug Administration (FDA) announced a Class I recall of Sterilmed’s Agilis Steerable Introducer...
The California Heart & Vascular Clinic in El Centro, Calif., treated the first post-FDA clearance patient with a DABRA atherectomy system. Athar Ansari, M.D.

The California Heart & Vascular Clinic in El Centro, Calif., treated the first post-FDA clearance patient with a DABRA system. 

Feature | Cath Lab| November 24, 2017 | Athar Ansari, M.D., FACC
As debates about the current state and future of healthcare rage in Congress, the media and healthcare settings acros
Videos | Cath Lab| November 08, 2017
Juan Granada, M.D., Cardiovascular Research Foundation president and chief executive officer, shares his insights on
Results of the ORBITA study found no difference in exercise time after six weeks in patients with stable angina who received percutaneous coronary intervention (PCI) versus a placebo treatment. TCT 2017
Feature | Cath Lab| November 06, 2017
November 6, 2017 – Results from ORBITA, a prospective multi-center randomized blinded placebo-controlled study, found
Culprit Lesion-Only PCI Improves Outcomes for Cardiogenic Shock Patients Compared to Multivessel PCI
News | Cath Lab| November 01, 2017
November 1, 2017 — Results from the prospective, randomized, multicenter CULPRIT-SHOCK trial found an initial strateg
Three-Year Quality of Life Improvements Similar for PCI and CABG in Left Main Disease
News | Cath Lab| October 30, 2017
October 30, 2017 — New study results from the EXCEL trial comparing the quality of life (QoL) of patients with left m
Corindus Evaluates Incorporating HeartFlow Technology With CorPath GRX System
Technology | Cath Lab| October 26, 2017
Corindus Vascular Robotics Inc. announced that it will incorporate the HeartFlow FFRct (fractional flow reserve-...
Shockwave Medical Announces $35 Million in New Financing
News | Cath Lab| October 24, 2017
October 24, 2017 — Shockwave Medical reported $35 million in new financing, an extension of the company’s previously
Overlay Init